Advantages of switching to elvitegravir/cobicistat/emtricitabine/tenofovir therapy in virologically-suppressed people living with human immunodeficiency virus/acquired immune deficiency syndrome

Detalles Bibliográficos
Autores principales: Fan, Lina, Li, Lei, Gao, Liying, Hu, Yue, Yu, Aiping, Zhang, Defa, Qiu, Chunting, Huang, Rong, Wu, Yue, Ma, Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9945251/
https://www.ncbi.nlm.nih.gov/pubmed/36574215
http://dx.doi.org/10.1097/CM9.0000000000002503

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9945251/
https://www.ncbi.nlm.nih.gov/pubmed/36574215
http://dx.doi.org/10.1097/CM9.0000000000002503

Ejemplares similares